AR077334A1 - Anticuerpos muc1 antimucina - Google Patents
Anticuerpos muc1 antimucinaInfo
- Publication number
- AR077334A1 AR077334A1 ARP100102737A ARP100102737A AR077334A1 AR 077334 A1 AR077334 A1 AR 077334A1 AR P100102737 A ARP100102737 A AR P100102737A AR P100102737 A ARP100102737 A AR P100102737A AR 077334 A1 AR077334 A1 AR 077334A1
- Authority
- AR
- Argentina
- Prior art keywords
- antimucine
- muc1 antibodies
- antibodies
- binding
- present application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021109P | 2009-07-31 | 2009-07-31 | |
| EP09009942A EP2281844A1 (en) | 2009-07-31 | 2009-07-31 | MUC 1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077334A1 true AR077334A1 (es) | 2011-08-17 |
Family
ID=41460131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102737A AR077334A1 (es) | 2009-07-31 | 2010-07-28 | Anticuerpos muc1 antimucina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9217038B2 (enExample) |
| EP (3) | EP2281844A1 (enExample) |
| JP (2) | JP5922018B2 (enExample) |
| KR (1) | KR101773506B1 (enExample) |
| CN (1) | CN102574926B (enExample) |
| AR (1) | AR077334A1 (enExample) |
| AU (1) | AU2010278302B2 (enExample) |
| BR (1) | BR112012002226A2 (enExample) |
| CA (1) | CA2768888C (enExample) |
| CU (1) | CU23972B1 (enExample) |
| EA (1) | EA029954B1 (enExample) |
| IL (1) | IL217827A (enExample) |
| MX (1) | MX2012000874A (enExample) |
| NZ (1) | NZ597563A (enExample) |
| SG (2) | SG10201404019XA (enExample) |
| WO (1) | WO2011012309A1 (enExample) |
| ZA (1) | ZA201200166B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539981A1 (en) | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| PL1920781T3 (pl) * | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| PT2603528T (pt) | 2010-08-10 | 2016-12-01 | Glycotope Gmbh | Anticorpos glicosilados em fab |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| EP2963126B1 (en) * | 2013-03-01 | 2019-04-03 | Saitama Medical University | Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| CA2938819A1 (en) | 2014-02-06 | 2015-08-13 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Antibody to mucin 4 (muc4) glycopeptide and uses thereof |
| US10239950B2 (en) * | 2014-04-28 | 2019-03-26 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof |
| WO2016026143A1 (en) * | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| CN116199790A (zh) | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| TWI780082B (zh) | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| EP3570881A4 (en) * | 2017-01-18 | 2020-08-19 | Nanocruise Pharmaceutical Ltd. | MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE |
| US20190343953A1 (en) | 2017-01-27 | 2019-11-14 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| WO2018178047A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| WO2018178046A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
| US20200148785A1 (en) * | 2017-03-29 | 2020-05-14 | Glycotope (GmbH) | Pd-l1 and ta-muc1 antibodies |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| NZ762505A (en) | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US12605469B2 (en) | 2017-10-02 | 2026-04-21 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| BR112020008001A2 (pt) * | 2017-10-24 | 2020-10-20 | Go Therapeutics, Inc. | anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica. |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| CN108982854B (zh) * | 2018-06-19 | 2021-07-27 | 哈尔滨医科大学 | 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用 |
| JP7541930B2 (ja) * | 2018-06-29 | 2024-08-29 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ１抗体およびその使用 |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| CN113631229B (zh) | 2019-03-25 | 2025-09-23 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
| WO2023121448A1 (en) * | 2021-12-21 | 2023-06-29 | Merus N.V. | Binding domains against cancer-associated muc1 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| TW202506190A (zh) | 2023-04-05 | 2025-02-16 | 日商第一三共股份有限公司 | 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
| JP3698370B2 (ja) | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
| US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6465220B1 (en) * | 1998-12-21 | 2002-10-15 | Glycozym Aps | Glycosylation using GalNac-T4 transferase |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| ATE290879T1 (de) | 1999-08-18 | 2005-04-15 | Altarex Medical Corp | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
| GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
| ES2524442T3 (es) | 2002-07-22 | 2014-12-09 | Glycotope Gmbh | Procedimiento para la producción de una mucina (MUC1) inmunoestimulante |
| DK1530628T3 (da) | 2002-08-16 | 2011-01-10 | Glycotope Gmbh | Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| SI1654353T1 (sl) | 2003-08-18 | 2013-09-30 | Glycotope Gmbh | Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe |
| CN103627670B (zh) | 2004-02-13 | 2016-12-21 | 格莱克托普有限公司 | 高活性糖蛋白加工条件及其有效生产方法 |
| EP3539981A1 (en) | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
-
2009
- 2009-07-31 EP EP09009942A patent/EP2281844A1/en not_active Withdrawn
-
2010
- 2010-07-28 AR ARP100102737A patent/AR077334A1/es not_active Application Discontinuation
- 2010-07-30 NZ NZ597563A patent/NZ597563A/xx unknown
- 2010-07-30 WO PCT/EP2010/004663 patent/WO2011012309A1/en not_active Ceased
- 2010-07-30 MX MX2012000874A patent/MX2012000874A/es active IP Right Grant
- 2010-07-30 CA CA2768888A patent/CA2768888C/en active Active
- 2010-07-30 US US13/387,587 patent/US9217038B2/en active Active
- 2010-07-30 EP EP18181262.9A patent/EP3421497A1/en not_active Withdrawn
- 2010-07-30 BR BR112012002226A patent/BR112012002226A2/pt not_active Application Discontinuation
- 2010-07-30 CN CN201080033969.9A patent/CN102574926B/zh active Active
- 2010-07-30 SG SG10201404019XA patent/SG10201404019XA/en unknown
- 2010-07-30 SG SG2012000865A patent/SG177527A1/en unknown
- 2010-07-30 EP EP10746999A patent/EP2459595A1/en not_active Withdrawn
- 2010-07-30 EA EA201270207A patent/EA029954B1/ru unknown
- 2010-07-30 AU AU2010278302A patent/AU2010278302B2/en active Active
- 2010-07-30 KR KR1020127005121A patent/KR101773506B1/ko active Active
- 2010-07-30 JP JP2012522029A patent/JP5922018B2/ja active Active
-
2012
- 2012-01-09 ZA ZA2012/00166A patent/ZA201200166B/en unknown
- 2012-01-30 IL IL217827A patent/IL217827A/en active IP Right Grant
- 2012-01-30 CU CU2012000019A patent/CU23972B1/es active IP Right Grant
-
2016
- 2016-01-04 JP JP2016000133A patent/JP6272916B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010278302B2 (en) | 2014-12-18 |
| SG10201404019XA (en) | 2014-09-26 |
| CU23972B1 (es) | 2013-12-27 |
| WO2011012309A8 (en) | 2011-04-07 |
| KR20120051724A (ko) | 2012-05-22 |
| ZA201200166B (en) | 2013-03-27 |
| JP6272916B2 (ja) | 2018-01-31 |
| NZ597563A (en) | 2013-08-30 |
| CA2768888A1 (en) | 2011-02-03 |
| CN102574926A (zh) | 2012-07-11 |
| CN102574926B (zh) | 2014-10-15 |
| US9217038B2 (en) | 2015-12-22 |
| IL217827A0 (en) | 2012-03-29 |
| BR112012002226A2 (pt) | 2016-11-08 |
| CU20120019A7 (es) | 2012-06-21 |
| AU2010278302A1 (en) | 2012-02-09 |
| EA029954B1 (ru) | 2018-06-29 |
| US20120128676A1 (en) | 2012-05-24 |
| JP5922018B2 (ja) | 2016-05-24 |
| SG177527A1 (en) | 2012-02-28 |
| EP2281844A1 (en) | 2011-02-09 |
| CA2768888C (en) | 2019-02-26 |
| MX2012000874A (es) | 2012-02-01 |
| EA201270207A1 (ru) | 2012-07-30 |
| EP2459595A1 (en) | 2012-06-06 |
| WO2011012309A1 (en) | 2011-02-03 |
| IL217827A (en) | 2017-05-29 |
| JP2013500703A (ja) | 2013-01-10 |
| EP3421497A1 (en) | 2019-01-02 |
| KR101773506B1 (ko) | 2017-08-31 |
| JP2016041771A (ja) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077334A1 (es) | Anticuerpos muc1 antimucina | |
| CL2011002003A1 (es) | Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer. | |
| CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
| CL2013000545A1 (es) | Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune. | |
| AR080873A1 (es) | Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3) | |
| CL2011002567A1 (es) | Anticuerpo antifactor de necrosis tumoral alfa (tnf-a) o fragmento de union del mismo; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno inmune. | |
| CL2011002784A1 (es) | Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo. | |
| CO2017006651A2 (es) | Anticuerpos anti-c5 | |
| MX2016007722A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| AR079551A1 (es) | Anticuerpos anti-her3 y usos de los mismos | |
| BR112016004324A2 (pt) | anticorpos | |
| BRPI0807710A8 (pt) | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica | |
| CL2011002611A1 (es) | Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17. | |
| MX2015008920A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
| CL2011002304A1 (es) | Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer. | |
| MX2017008978A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. | |
| MX2015009594A (es) | Construcciones de anticuerpos para cdh19 y cd3. | |
| CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
| AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
| CL2013001403A1 (es) | Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso. | |
| CL2012002328A1 (es) | Anticuerpo aislado anti-tat419 que inhibe la proliferación celular; ácido nucleico que lo codifica; célula que lo produce; método para identificar anticuerpos que unen un epítopo antigénico tat419; método para inhibir la proliferación de una célula que expresa un péptido tat419; y su uso en el tratamiento de tumores cancerígenos. | |
| NZ704718A (en) | Epcam aptamer for detection of cancer stem cells | |
| CL2008002233A1 (es) | Anticuerpo o un fragmento del mismo que reconoce especificamente el receptor ephb4; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer. | |
| AR095199A1 (es) | Anticuerpos anti-cd52 | |
| AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |